OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis → The biggest lie in America unravels… (From Stansberry Research) (Ad) Free MATN Stock Alerts $0.04 0.00 (0.00%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.13▼$0.38Volume16,770 shsAverage Volume338,444 shsMarket Capitalization$3.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Mateon Therapeutics alerts: Email Address Ad Stansberry ResearchThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerful investors are starting to take notice. Make no mistake, we're going to be seeing the ripple effects from this story play out for many years to come. I just released video about it. (You'll see why, when you watch it.) About Mateon Therapeutics Stock (OTCMKTS:MATN)Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.Read More MATN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MATN Stock News HeadlinesFebruary 27, 2024 | wsj.comViking Therapeutics Inc.February 25, 2023 | benzinga.comSorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummarySee More Headlines Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2019Today6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CUSIPN/A CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.20Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$3.58 million OptionableNot Optionable Beta1.33 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Vuong Trieu (Age 58)Chairman & CEO Comp: $166.53kMr. Amit Shah (Age 54)Chief Financial Officer Comp: $66.5kDr. Chulho Park Ph.D. (Age 54)Chief Technology Officer Comp: $129.86kDr. Larn Hwang (Age 58)Chief Scientific Officer Dr. Anthony E. Maida III (Age 69)M.A., M.B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director Dr. Seymore Howard Fein (Age 72)Chief Medical Officer Mr. Saranjit SaundCBO & GM of AI DivisionMr. Burcak BeserCTO of AI DivisionMore ExecutivesKey CompetitorsVicapsys Life SciencesOTCMKTS:VICPNeuroSense TherapeuticsNASDAQ:NRSNPurple BiotechNASDAQ:PPBTNovelion TherapeuticsOTCMKTS:NVLNFMonopar TherapeuticsNASDAQ:MNPRView All Competitors MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed in 2024? Mateon Therapeutics' stock was trading at $0.0383 at the beginning of 2024. Since then, MATN stock has increased by 3.8% and is now trading at $0.0397. View the best growth stocks for 2024 here. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) issued its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Oramed Pharmaceuticals (ORMP), Synergy Pharmaceuticals (SGYP), VIVUS (VVUS), Idera Pharmaceuticals (IDRA), Ascent Solar Technologies (ASTI), BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MATN) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | SponsoredInvest in the Firm Revolutionizing Brain HealthThey've engineered a patented transport vehicle that effectively "smuggles" drugs across the blood-brain barri...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mateon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.